Investor Materials

2017 Annual Report

View a digital enhanced version of our Annual Report.

2018 Proxy Statement

View a digital enhanced version of our Proxy Statement.

Vote Online

Your Vote is IMPORTANT! Vote online with any device. Vote by phone by dialing 866-356-9132.

* Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.

Date

Time

Location

Genprex is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.